What To Expect From Charles River Laboratories’s (CRL) Q3 Earnings

Charles River Laboratories gears up for its earnings release on November fourth, following a surprise beat of revenue forecasts by 4.6% last quarter. Despite flat revenue, organic revenue and earnings per share outperformed expectations. Wall Street projects a slight revenue dip of 1.5% and adjusted earnings per share of $2.34 for this quarter. Meanwhile, peer companies like Medpace and West Pharmaceutical Services have shown impressive growth, with Medpace's revenue climbing nearly 24% and West Pharmaceutical's revenues rising nearly 8%. Charles River's stock is up 2% heading into the earnings call, with analysts predicting a price target above its current trading value. Investors and analysts await Charles River's performance to see if it can maintain its reputation for beating expectations amidst a stable drug development services market.The Daily News Now! — Every city. Every story. AI-powered. Hosted on Acast. See acast.com/privacy for more information.